Squarepoint
VKTX icon

Squarepoint’s Viking Therapeutics VKTX Stock Holding History

Squarepoint’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.57M Sell
78,900
-10,800
-12% -$347K ﹤0.01% 2003
2025
Q4 		$3.16M Sell
89,700
-12,500
-12% -$443K ﹤0.01% 1768
2025
Q3 		$2.69M Buy
102,200
+48,000
+89% +$1.43M ﹤0.01% 1862
2025
Q2 		$1.44M Sell
54,200
-69,900
-56% -$1.84M ﹤0.01% 2348
2025
Q1 		$3M Buy
124,100
+95,700
+337% +$3.02M ﹤0.01% 1781
2024
Q4 		$1.14M Buy
28,400
+7,300
+35% +$416K ﹤0.01% 2937
2024
Q3 		$1.34M Buy
+21,100
New +$1.24M ﹤0.01% 2379

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Squarepoint's VKTX Position: Q3 2025 in Review

Squarepoint sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 55,355 shares — an estimated $1.65M sold.

Squarepoint first reported a position in VKTX in Q4 2018 and held it in 22 quarters. The position peaked at $10.8M in Q4 2024. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Squarepoint reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Squarepoint sold 55,355 Viking Therapeutics shares in Q3 2025, an estimated $1.65M.
  • Squarepoint first reported a position in Viking Therapeutics in Q4 2018 and held it in 22 quarters.
  • Squarepoint's Viking Therapeutics position peaked at $10.8M in Q4 2024.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.